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DOI: 10.1039/c2sc20627gA critical discussion is presented about the possible role of Pt–protein interactions in the mechanisms of
action of platinum anticancer compounds. Although, since 40 years from its discovery, cisplatin and
analogues are believed to exert their therapeutic effects via direct interactions with nucleic acids, several
proteins/enzymes have recently appeared to be involved in the compounds’ overall pharmacological
and toxicological profiles, apart from classical serum transport proteins and metal detoxification
systems. As an example, the emerging role of zinc finger proteins is noteworthy in the activity of
platinum drugs. Moreover, the pursuit of novel platinum candidates that selectively target enzymes is
now the subject of intense investigation in medicinal bioinorganic chemistry and chemical biology. An
overview is presented of the most representative studies in the field, with particular focus on the
characterization of the Pt–protein interactions at a molecular level, using different biophysical and
analytical methods.1. Introduction
Platinum coordination compounds, well known before Alfred
Werner classified coordination compounds1 and one of them,
cisplatin, recognized as anticancer drug in the late 1960s,2–4 have
been studied intensely for several decades now. Most recently,
the major aim to study these compounds stems from the wish to
learn about their mechanisms of pharmacological action in the
expectation to improve administration protocols and making
new drugs. This work has been reviewed regularly,5–8 including
by one of us.9–11 During the last four decades a strong focus has
been on the irreversible (kinetically inert) binding of such plat-
inum compounds to DNA, resulting in halting the cell divisions
and leading to apoptosis. However, even from laboratory coor-
dination chemistry experiments it is predictable that Pt-amine
compounds would also react with proteins.
In this minireview we will focus on the latter biological targets
and explore the evidences of Pt–protein binding relevant to the
drug’s mechanisms of action. Indeed, until 2006, only a limited
number of biophysical studies have appeared dealing with the
interactions of anticancer metallodrugs with proteins. These
studies mostly concerned the two major serum proteins, albumin
and transferrin, involved in the transport of metallodrugs, as wellaPharmacokinetics, Toxicology and Targeting, Research Institute of
Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV
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This journal is ª The Royal Society of Chemistry 2012as metallothioneins, small, cysteine-rich intracellular proteins,
primarily involved in storage and detoxification of soft metal
ions, including some early work by one of us.12–15
Subsequently, the general consensus on the crucial role of the
interactions of metallodrugs with protein targets in determining
the compounds’ pharmacological action, uptake and bio-
distribution, as well as their overall toxicity profile, resulted the
number of studies to increase exponentially.16,17 Nowadays,
cisplatin and related compounds are known to bind to several
classes of proteins with different roles, including transporters,
antioxidants, electron transfer proteins, DNA-repair proteins, as
well as proteins/peptides simply used as model systems to char-
acterize the reactivity of metallodrugs in vitro, but that are also
present in vivo. Recently, a study by Bischin et al.18 has reviewed
the Pt-species bound to proteins; in fact, many of the reported
crystallographic structures are also available in the Heavy Atom
Database (HAD) in relation to the heavy atom replacement
methodology, and not always refer to Pt-based anticancer
compounds.
Below, we will discuss in detail about the various proteins/
enzymes that have been studied so far and that have been shown
to interact with platinum anticancer drugs. We shall also
comment on how the investigational approach has evolved in this
field from studies involving simple amino-acid models to model
peptides and proteins, or even protein mixtures/cell extracts.
Attention will be paid to those proteins that influence the
mechanisms of action of platinum drugs at different levels, from
contributing to metal transport and uptake, to being real phar-
macological targets. For proper understanding, a brief descrip-
tion of the novel techniques and methodologies to characterize












































View Article Online2. Anticancer platinum compounds and initial studies
of their interactions with proteins
The success of cisplatin (cis-diamminedichloridoplatinum(II); cis-
Pt(NH3)2Cl2) in the clinic has resulted in numerous derivatives as
second- and third-generation drugs (see Fig. 1 for a selection).
Any chemotherapeutic treatment of cancers, worldwide, is
currently done with a combination of anticancer drugs, to reduce
the toxic side effect of single compounds. In fact, 50% of all these
combinations nowadays contain a platinum drug. In more recent
years, we and others have been looking at more complicated
compounds, such as dinuclear, trinuclear and even mixed-metal
heteronuclear Pt(II), and even Pt(IV) compounds have been the
subject of investigation.10,11,19
In Fig. 1 we have included a selection of the most recently
synthesized drugs, based on improved kinetics (picoplatin),20 oral
administration (satraplatin),21 dinuclear azolate bridged
compounds,22,23 trinuclear diamine-bridged species,24 and a
group of compounds where a tail on the side arm can contain
either another metal such as Cu,25 or Ru,19,26 or an inter-
calator.10,27 The reader should realize that there are many more
examples and for details we refer to reviews of others and us.28–32
The design of these compounds has in most – if not all – cases
been based on their (improved) binding to DNA, in particular at
guanines. However, as previously mentioned, important findings
have been reported in the literature revealing that metal-based
drugs of different families, including Pt complexes, can target
proteins and enzymes in vitro.33 Moreover, direct interactions
with proteins have been demonstrated to take active roles in the
mechanisms of action of cisplatin, either affecting the sensitivity
of certain cancer cells to platinum-induced DNA damage (as
reported for the high-mobility group proteins (HMG)),34 or in
the development of cancer cell resistance to Pt treatment.35 In
2008 Davey et al. reported an X-ray crystallographic and
biochemical investigation of the reaction of cisplatin and oxali-
platin with nucleosome core particle and naked DNA, revealing
that histone octamer association can modulate DNAFig. 1 Clinically used platinum anticancer com
3136 | Chem. Sci., 2012, 3, 3135–3144platination.36 Platinum adduct formation was found to occur not
only at DNA sites, but also at specific histone methionine resi-
dues, which could serve as a nuclear platinum reservoir influ-
encing adduct transfer to DNA.
Within this frame, HSAB (hard soft acid base) theory predicts
that cisplatin, being a soft metal, has a high affinity to sulfur-
containing ligands. Indeed, sulfur-containing proteins and
peptides do play a significant role in the functioning of platinum
drugs, because of their high affinity for platinum, their abun-
dance (e.g. albumin), and their involvement in metal–ion trans-
port. It is unclear how platinum coordination compounds can
generate DNA adducts with so many competing sulfur-donor
ligands in the cell.37 Initially, model amino acids have been used
as representative systems to characterize the mechanisms of Pt–
protein binding. These first experiments improved the under-
standing of the metabolite form, by which the metal complex
enters the tumour cells, and whether and how this metabolized
complex is already inactivated at this time.38 Thus, efficient
analytical speciation methods were introduced into this impor-
tant field of research to investigate the mechanisms of action of
Pt-chemotherapeuticals, mostly based on various HPLC sepa-
ration techniques hyphenated to sensitive and selective detectors.
In this context inductively coupled plasma mass spectrometry
(ICP-MS) has been crucial due to the relative simplicity in
measuring online signals of Pt-containing species (hydrolysis
products and metabolites) from anticancer drugs. The findings
from HPLC-ICP-MS have been further complemented by
structural information, for example by electrospray ionization
mass spectrometry (ESI-MS). In order to elucidate rapid kinetic
changes even capillary electrophoresis (CE) techniques were
employed for fast separation of Pt species.39
Using the above-mentioned techniques it was shown that
DNA is the thermodynamically favoured bound end product,
whereas the platinum-containing agents react more rapidly with
other ligands, such as thiolates and thioethers.37 Several studies
have been reported in the 1990s; to be mentioned are the work of
Sadler and co-workers on the activation of cisplatin towardspounds and a selection of active derivatives.












































View Article Onlinenucleoside binding upon reaction with Met residues,40,41 and the
results of Lempers et al. on binding to proteins and GSH.12–14
Studies on methionine and other sulfur donors suggest that
platinum species may migrate, after initial binding to sulfur-
containing ligands, to DNA in vivo.37 As such, because of their
ubiquity in the cell nucleus, the histone methionine residues
mentioned above could serve as an important pool for transfer of
Pt adducts to the DNA.
Concerning metallodrug–intact protein interactions, a series of
pioneering studies based on ESI-MS, and carried out during the
1990s and early 2000s, highlighted the advantages of this method
and defined the experimental conditions for its application to
simple metallodrug–protein samples. Most of these studies
focused on the reactivity of cisplatin and analogues with ubiq-
uitin (Ub), taken as the reference model protein, and in some
cases aimed at determining the competitive binding of platinum
complexes with other biological nucleophiles.42–45 Interactions of
Pt(II) drugs with other model proteins (cytochrome c, superoxide
dismutase, lysozyme, myoglobin), or mixtures of them, were
further investigated, also by one of us, by various techniques
including MS, NMR, ICP-OES and X-ray crystallography to
provide a description of the system at a molecular level.46–54
Fig. 2 depicts the global X-ray structure of cisplatin bound to hen
egg white lysozyme (HEWL, PDB 2I67).
In general, the obtained results implied that platinum drugs
dissolved in biological media – thus, in the presence of many
chemical components, including macromolecules – can manifest
a chemical reactivity that is profoundly distinct from that
observed when they are just dissolved in simple buffered solu-
tions. These observations posed important ‘‘caveats’’ for
researchers to extrapolate the behaviour observed in solution for
metallodrugs to that believed to occur inside cells.
Similar studies on the interactions of platinum compounds
with hemoglobin (Hb) were performed to provide evidence that
binding of platinum to Hb might lead to side effects in vivo. Hb is
a globular tetrameric protein consisting of four subunits held
together through non-covalent interactions, each with a Mw of
about 15–16 kDa. Each protein subunit is an individual molecule
that joins to its neighbouring subunits through intermolecularFig. 2 2Fo  Fc map at 1s covering cisplatin/HEWL adduct, covering
platinum(II) (magenta) that interacts with Ne of His 15 and with two
ammonia ligands (blue) with the relative bond lengths (A) indicated.
Reproduced using the coordinates of ref. 47.
This journal is ª The Royal Society of Chemistry 2012interactions and carries a heme group having Fe as the central
atom. Mass spectrometry studies proved that platinum drugs
bind Hb at clinically relevant concentrations, while heme release
was also observed upon Pt binding.55 Moreover, cysteine and
proline residues were shown to be involved in the Hb–Pt inter-
action. In the case of oxaliplatin, MS/MS identification of the
parent oxaliplatin and the Pt(dach) [dach ¼ 1,2-dia-
minocyclohexane] moiety in the Hb adducts supports the
hypothesis that an extensive amount of oxaliplatin bound to the
Hb in erythrocytes may lead to a reduced dose of oxaliplatin
available for DNA binding.
Interestingly, the activation of the Pt(IV) compound satraplatin
by haemoglobin, cytochrome c and liver microsomes was
observed in vitro combining HPLC-ICP-MS and visible
absorption spectrophotometry, suggesting a possible role of
metal-containing redox proteins acting as reducing agents for the
Pt centre.56
It must be noted that thanks to the fast development of high-
resolution analytical methods in recent years, it has been possible
to re-analyse and further characterize some of the above
mentioned Pt–protein samples. As an example, the interaction
between oxaliplatin and the model protein Ub was investigated
in a top-down approach by means of high-resolution ESI-MS,
using diverse tandem mass spectrometric (MS/MS) techniques,
including collision-induced dissociation (CID), higher-energy
C-trap dissociation (HCD), and electron transfer dissociation
(ETD).57 Similarly, high-resolution Fourier-transform ion
cyclotron resonance mass spectrometry (FT ICR-MS) studies
provided further evidence for cisplatin as a protein cross-linking
reagent.58,59 In some cases, comparison of different ionization
techniques, i.e. matrix-assisted laser desorption/ionization
(MALDI) and nanoelectrospray ionization mass spectrometry
(nESI-MS), for the analysis of small protein–Pt anticancer drug
interactions, was possible.60
In very recent years, more complex systems have been analysed
and examples of metallomics strategies based on different tech-
niques (e.g. NMR,61 fluorescence, MS or X-ray absorption
spectroscopy (XAS)), and applied either on cell extracts or
directly on cells, appeared in the literature, mainly aiming at
determining biological targets, metallodrug distribution, as well
as metal speciation.62,63 For example, interesting information on
the cellular targets of cisplatin came from a study where E. coli
cells were treated with the drug, and multidimensional liquid
chromatography and electrospray ionization tandem mass
spectrometry were used to identify as many as 31 proteins to
which platinum was bound.64 These included high abundance
enzymes and ribosomal proteins, as well as DNA- and RNA-
binding proteins. One of the most interesting results of that study
was that, contrary to what one would expect from HSAB theory,
according to which both Cys and Met would be the primary
binding sites for cisplatin on proteins, carboxylate and hydroxyl
groups were identified as the platinum coordination sites in 18
out of 31 proteins and Met was identified as the binding site only
9 times, while no binding to cysteine was reported.
In other studies, Hambley et al. showed that X-ray absorption
near edge spectroscopy (XANES) can be used to identify the
distribution and oxidation states of Pt(II) and Pt(IV) in cells and in
spheroids.65,66 [1H,15N] HSQC NMR spectroscopy was also












































View Article Onlinein aqueous extracts of cancer cells. Interestingly, from these latter
studies glutathione (GSH) appeared not to be the major target of
cisplatin in the cytoplasm.67
Monitoring biotransformation products of platinum drugs in
tissue is certainly an advance investigation in medicinal inorganic
chemistry. Esteban-Fernandez et al. performed in vivo studies by
administering platinum drugs to experimental rats and exam-
ining Pt–protein binding in the kidney and the inner ear by using
2D liquid chromatography coupled to ICP-MS to elucidate the
severe induced nephrotoxicity and ototoxicity.68 The results
clearly indicated that not only the total Pt content, but rather the
actual Pt-containing species are the responsible factor for the
alteration of organ functions. Moreover, speciation studies
revealed complete Pt binding to proteins. More recently, matrix-
assisted laser desorption/ionization time-of-flight (MALDI-
TOF) imaging was applied to study the spatial distribution of
oxaliplatin in tissue sections of rat kidneys.69 The obtained
results showed that oxaliplatin was localized at the periphery of
the kidney, suggesting that the drug cannot penetrate deeply into
the organ, thereby explaining its reduced nephrotoxicity in
comparison to cisplatin.3. Proteins involved in the transport and resistance
mechanisms of platinum drugs
3.1 Introduction
Although most patients initially do respond well to platinum-
based chemotherapy, a considerable percentage eventually
develop drug resistance and relapse. Platinum resistance is
considered multi-factorial and includes both mechanisms that
limit the formation of platinum–DNA adducts, as well as
mechanisms that prevent cell death following drug-induced
damage.70–74 Among the mechanisms limiting Pt–DNA adduct
formation the following two have been recognized: (i) impaired
transport leading to reduced platinum accumulation;75 and (ii)
inactivation of platinum compounds by sulfur-containing
molecules. In both cases the direct interaction of Pt drugs with
proteins plays a major role, as will be discussed below.
Reduced cellular accumulation of platinum either by impaired
uptake or increased efflux is often found in cells selected for
cisplatin resistance, both in vivo and in vitro, and is generally
considered as one of the most consistent characteristics of plat-
inum resistant cells.75 Facilitated or active transport systems, as
well as passive diffusion, are both relevant for the cellular uptake
of platinum drugs.76,77 In addition, general drug uptake/efflux
systems in the intestine, liver and kidney are increasingly found
to be important and may have a major impact on drug disposi-
tion and response to platinum-based chemotherapy.78
Concerning transport mechanisms for Pt drugs, a series of
experimental evidences, well reviewed by Hall et al.,79 leads to
conclude that cisplatin most likely enters the cell via two path-
ways: (a) passive diffusion and (b) facilitated and active uptake
by a number of transport proteins, like CTR1.80 Initially, passive
diffusion through the cellular lipid bilayer was considered to be
the dominant process involved in drug uptake and distribution.
However, more recently the concept of carrier mediated and
active uptake of commonly prescribed drugs has become the rule
rather than the exception.81 Thus, membrane transporters and3138 | Chem. Sci., 2012, 3, 3135–3144channels, collectively known as the transportome, are increas-
ingly recognized as important determinants of tumour cell che-
mosensitivity and chemoresistance. Membrane transporters of
platinum-based anticancer agents determining active platinum
uptake and efflux pathways, as well as their clinical significance
have recently been reviewed by Burger et al.,82 including organic
cation transporters (OCTs) belonging to the SLC22 subfamily,
solute carriers (SLCs) and ATP-binding cassette (ABC) multi-
drug transporters. Here, we aim at recalling only those that have
been most studied and characterized by both pharmacological
and biophysical methods, namely the copper influx transporters
(CTRs), as well as the copper chaperon protein Atox1. In addi-
tion, a paragraph on serum proteins albumin and transferrin as
possible platinum transport systems will be also included.
Concerning the resistance mechanisms to Pt drugs we will
primarily summarise and discuss the studies on metallothioneins
(MTs), even though several other proteins/peptides are also
involved.35 For example, increased levels of both P-glycoprotein
(Pgp) and glutathione-S-transferases have been correlated to
drug resistance in certain tumours and inhibitors of both proteins
have been used in combination therapies with, for instance,
cisplatin.3.2 Copper transporters and chaperons
Copper transporters have been proposed to be involved in
cellular import and export of platinating agents, as well as in
cisplatin resistance mechanisms.80,83 In particular, expression of
the human copper transporter 1 (hCTR1) is thought to result in
increased sensitivity to cisplatin, whereas expression of two Cu(I)
proteins exporting ATPase, i.e. ATP7A and ATP7B, is believed
to be involved in the resistance to cisplatin, either by sequestering
drug away from its targets (ATP7A), or by exporting the drug
from the cell (ATP7B). CTR1 (copper transporter 1, SLC31A1)
is an evolutionarily conserved copper influx transporter present
in plants, yeast, and mammals, and is the main copper importer
in mammalian cells. The human version, hCTR1, is expressed in
all tissues and is a key player in the homeostatic regulation of
intracellular copper levels, to ensure that nutritional delivery of
copper to enzymes, such as cytosolic Cu,Zn-superoxide dis-
mutase. hCTR1 is located in the plasma membrane and is
constituted by three transmembrane helices, an extracellular N-
terminal domain and a cytosolic C-terminal domain.84 Three
hCTR1 molecules form a symmetric trimer with a channel-like
architecture, as revealed by electron microscopy. Interestingly,
methionine (Met)-rich motifs located in the N-terminal domain
and in the inner side of the channel pore are critical for the
binding of copper.85
hCTR1has been shown to play an essential role in the cyto-
toxic effects of platinum drugs in cancer cells.86 Moreover,
cisplatin treatment of a cell line expressing hCTR1 revealed the
time- and concentration-dependent appearance of a stable
hCTR1 multimeric complex, consistent with a homotrimer,
which was not observed following copper treatment of these
same cells. Mutagenesis studies identified two methionine-rich
clusters in the extracellular amino-terminal region of hCTR1 that
were required for stabilization of the hCTR1 multimer by
cisplatin, suggesting that these sequences bind cisplatin and,
subsequently, form crosslinks between hCTR1 polypeptides.87This journal is ª The Royal Society of Chemistry 2012
Fig. 3 Representation of the crystal structure of cisplatin bound to an












































View Article OnlineNatile and co-workers investigated the binding of platinum
complexes to the Met-rich domain by different techniques
including mass spectrometry and NMR spectroscopy.88 Accord-
ing to their findings, cisplatin appears to easily form adducts with
the peptide domain, in which all the original ligands of Pt are lost
and replaced by the S-donor Met groups. On the basis of these
observations cisplatin would be actually sequestered by hCTR1
and not transported, while a possible transport system could be
actually an endocytotic process, incorporating a portion of the
extracellular milieu (containing non-degraded cisplatin) into
vesicles, which are subsequently delivered to subcellular
compartments. These latter results might be in accordance with a
more recent paper reporting on the fact that overexpression of
hCTR1 in the human embryonic kidney (HEK) cell line did not
result in increased sensitivity to cisplatin.89 Other studies based
on MS and NMR spectroscopy characterized the binding of
platinum compounds with synthetic peptides corresponding
to hCTR1 Mets motifs at a molecular level, in some cases
highlighting the differences among the various Pt drugs.90,91
Once platinum enters the cells, although many different
systems appear implicated in cisplatin trafficking, mounting
evidence suggests a linkage between cisplatin resistance and the
human copper homeostatic proteins Atox1 and ATP7A or
ATP7B.92 The copper chaperone Atox1 binds Cu(I) at a
conserved CXXC motif and delivers it to the N-terminal metal
binding domains (MBDs) of ATP7B and ATP7A, which are
Cu(I) specific P1B-type ATPases. Each human Cu(I) ATPase has
six MBDs, which also bind Cu(I) with CXXC motifs and
resemble Atox1 in the overall structure.93 The structure of a
stoichiometric cisplatin–Atox1 adduct (Pt-Atox1) was deter-
mined at 1.6 A resolution showing a Pt(II) ion coordinated to
Cys12 and Cys15 from the CXXC motif.94 The geometry is
square planar with the two cysteine ligands oriented trans to one
another. The remaining ligands are provided by the backbone
amide nitrogen of Cys12 and an exogenous donor best modelled
as a 2-carboxyethylphosphane (TCEP) molecule with a
TCEP(P)–Pt distance of 2.48 A (Fig. 3). In the same paper the
structure of a dimeric cisplatin adduct Pt-(Atox1)2 was also
reported at 2.14 A resolution. Overall, the two structures support
the idea that the cisplatin interaction with Cu(I) binding motifs
leads to unfavourable therapeutic outcomes, not only due to
unproductive cisplatin trafficking, but perhaps also as a result of
aberrant Cu(I) transport in cisplatin resistant tumours.
Using solution and in-cell NMR spectroscopy to probe the
interaction of cisplatin with the human Atox1 in a physiological
environment, Arnesano et al. showed that Pt binding to the Cu
chaperone follows at least two steps: initially a Pt-Atox1 adduct
is formed, while at longer reaction times protein dimerization
and loss of the ammines from cisplatin are observed.95 Such a
process is reminiscent of the copper-promoted formation of
Atox1 dimers which have been proposed to be able to cross the
nuclear membrane and act as a transcription factor. In the same
paper it was reported that overexpression of Atox1 in E. coli
reduces the amount of DNA platination and, consequently, the
degree of cell filamentation, suggesting a possible mechanism of
resistance to cisplatin chemotherapy associated to over-
expression of Cu transporters in cancer cells. Finally, it is worth
mentioning that other recent NMR studies described Atox1
unfolding induced by cisplatin.96This journal is ª The Royal Society of Chemistry 20123.3 Serum proteins
Upon intravenous application reactions of cisplatin with human
serum proteins, both albumin (HSA) and transferrin (Tf) are
thought to play an important role in the metabolism of this
anticancer drug. HSA is the most abundant protein (about 52%
of total serum protein) with a concentration of 40–45 g L1 in
healthy humans (ca. 600 mM; Mw 66–67 kDa). It comprises a
single chain of 585 amino acids organized in three similar
domains, each composed of two subdomains.97 HSA is known to
bind a remarkably wide range of drugs, thereby restricting their
free, active concentrations.98 Reducing this binding affinity
represents a major challenge in drug development. However,
HSA can also be exploited for targeted delivery strategies to
develop compounds that can selectively accumulate in tumour
cells, including platinum complexes.99,100
Concerning platinum drug binding to HSA several reports
have appeared in the literature; however, still conflicting infor-
mation is available concerning the actual Pt preferential binding
sites on HSA. According to NMR spectroscopic studies, a
Met298 S,N-macrochelate is a major cisplatin binding site, and
monofunctional adducts involving Cys34 and surface histidine
residues are also known to be formed.101Multidimensional liquid
chromatography coupled with tandem mass spectrometry (LC-
MS/MS) analysis of serum samples treated with cisplatin for 3 h
identified a total of five specific binding sites of Pt for HSA,
including the cysteine residue Cys34, two methionine sites
(Met329, Met548) and the tyrosine and aspartate O-donor sites
Tyr150 (or Tyr148) and Asp375 (or Glu376).102 Similarly, when
CE was applied to assess cisplatin interactions with HSA, strong
metal–protein coordination appeared to occur at several HSA
sites.103 Recently, the combination of tryptic digestion with LC-
MS/MS analysis has provided additional information revealing
that cisplatin can crosslink His67and His247 at the interface
between domains I and II, that are part of the major zinc binding












































View Article OnlineThe interactions of polynuclear platinum complexes analogues
of the trinuclear BBR3464 (Fig. 1) with HSA were also studied
by various techniques. Evidence for pre-association, presumably
through electrostatic and hydrogen-bonding, was obtained from
fluorescence and circular dichroism spectroscopy and ESI-MS.
When such compounds contain Pt–Cl bonds, further reaction
will take place presumably through displacement by sulfur
nucleophiles. The interaction, but not deactivation, of the
reported Pt complexes on HSA suggests a new and promising
pathway for a polynuclear platinum drug.105
To study the carboplatin–serum proteins interaction, a sensi-
tive method using size exclusion chromatography coupled to
inductively coupled plasma mass spectrometry (SEC-ICP-MS)
was developed.106 The results showed that carboplatin–albumin
and carboplatin–globulin complexes were formed after the
infusion of carboplatin, and the concentration of all platinum
species decreased as the species were metabolized and continu-
ously excreted from the human body. Besides the primary one-
to-one binding of Pt to proteins, also aggregation of proteins was
observed. This aggregation may result either from the cross-
linking of proteins through platinum, or from an association
facilitated by platinum. It is worth mentioning that Szpunar et al.
were the first to use hyphenated speciation techniques with SEC-
ICP-MS to investigate interaction of cisplatin with serum.107
Afterwards, other groups approached the problem of platinum
drugs quantification in serum and plasma. These latter studies
have been recently reviewed by Michalke,38 and we refer the
reader to that paper for deeper insight in the methodology.
Human serum transferrin (Tf) is a single-chain glycoprotein
containing 679 amino acids with a molecular mass of about
80 kDa and is found in blood at a concentration of about
2.5 g L1 (35 mM). Tf acts as an iron transporter and is capable of
binding two iron(III) ions (Fe3+ is bound selectively over Fe2+).108
Tf is normally only 30% saturated with iron in the body, and at
least 30 other metal ions can also bind to Tf.109 Therefore, it is
possible to use Tf as a metal transporter within the body and the
cellular uptake mechanism via the Tf-transferrin receptor trans-
port system has the potential to be exploited for site-specific
delivery of various therapeutic metal ions, drugs, proteins and
genes.110 In the case of metallodrugs the resulting Tf-conjugates
may significantly improve the cytotoxicity and selectivity of the
drugs itself. Thus, ESI coupled to Q-TOFmass analyser has been
widely used to characterise the interaction of cisplatin and oxa-
liplatin with human serum transferrin, and allowed to determine
the binding of cisplatin to a specific threonine residue.111–113 It is
worth mentioning that previously reported NMR studies by Cox
et al. revealed Pt binding to several Met residues of Tf.114
Recently, one of us developed a method based on the coupling
of high-resolution size-exclusion liquid chromatography (SEC),
using a polymer stationary phase with ICP-MS. This approach
was applied to study the interactions of cisplatin with the serum
proteins albumin and transferrin.115 Metal binding was found to
be dependent on the protein concentration and on the incubation
time of the sample. Cisplatin was found to be moderately reactive
towards the proteins without any discrimination/selectivity, in
accordance with the results obtained by an ESI-MS based
approach to study drug binding to protein mixtures.49
Moreover, cisplatin binding to a cysteine residue in a model
peptide resembling the Tf binding pocket for Fe ions3140 | Chem. Sci., 2012, 3, 3135–3144(239KDCHLAQVPSHTV251), appeared to be the most favoured
according to MS data, although it is worth mentioning that the
Cys residue is involved in a disulfide bridge in the native protein.3.4 Metallothioneins
Human metallothioneins (MTs) are a class of small (ca. 7000 Da)
cysteine- and metal-rich proteins, abundant in most human
tissues. They are represented by four highly conserved isoforms
(MT-1/-2/-3/-4). MT-1 and MT-2 occur ubiquitously in high
amounts in mammalian cells, and in contrast to MT-3/-4, the
biosynthesis of MT-1/-2 is induced by a variety of compounds,
including hormones, cytokines and metal compounds, such as
cisplatin.116,117HumanMTs are composed of a single polypeptide
chain of 61–68 amino acids including 20 cysteines. The cysteine
thiolates are involved in the binding of up to seven divalent metal
ions, forming two independent metal–thiolate clusters in which
each metal is tetrahedrally coordinated by both terminal and
bridging thiolate ligands.118–120 Naturally occurring MTs usually
contain seven Zn(II) ions. However, these metals can be displaced
by other metal ions in vivo that have a higher affinity for thiolates
such as Cd(II), Hg(II) and Pt(II), and the molecular mechanisms of
the Pt(II) interactions with MT-1/-2 have been the subject of
numerous studies.121 Of note, the reactions of human Zn7MT-2
with twelve cis/trans-[Pt(N-donor)2Cl2] compounds, including
new generation drugs, were investigated by ESI-MS and the Pt-
adducts characterized. A comparison of reaction kinetics
revealed that trans-Pt(II) compounds do react faster with
Zn7MT-2, replacing zinc, than cis-Pt(II) compounds do.
122 The
characterization of the products showed that, while all ligands in
cis compounds were replaced by cysteine thiolates, the trans
isomers retained their N-donor ligands, thus remaining in a
potentially active form. Recently, one of us studied competitive
binding of cisplatin towards a mixture of ubiquitin and MT-2 by
ESI-MS, showing that the drug has poor selectivity towards the
selected proteins and can form adducts with both peptides.1234. Possible targets: zinc-finger proteins
Several protein systems and enzymes need zinc ions to perform
their biological function. Classification of zinc sites in proteins is
generally into two categories: (i) catalytic sites with the presence
of a readily exchangeable water ligand coordinated to the zinc
(i.e. hydrolases) and (ii) structural sites with no coordinated
water and only protein residues in the coordination sphere. This
‘‘coordinative saturation’’ has as its purpose the creation or
maintenance of an appropriate secondary/tertiary structure in
the protein (i.e. zinc fingers or superoxide dismutase).124
Structural zinc covers an important area and is described by
ligation of four protein-derived histidine and/or cysteine ligands
yielding a coordinatively saturated central metal ion, and
prominent amongst these sites are the zinc fingers. From the
human genome sequencing project, it has become apparent that
the zinc-finger proteins themselves constitute 2–3% of the entire
human genome, and are the most common DNA binding motifs
found in human transcription factors.125,126 The diverse range of
biological functions of zinc-fingers and zinc-finger-like proteins
includes DNA recognition, RNA packaging, transcriptional












































View Article Onlineassembly, contributing to the manifestation of fundamental
cellular processes such as development, differentiation, and
tumour suppression. The zinc finger (ZF) motif, first described in
the transcription factor TFIIIA from the clawed toad Xenopus
laevis,127 exhibits a notably diverse array of structure and func-
tions, the latter involving important cellular processes such as
transcription, DNA repair, cellular signalling, metabolism and
apoptosis. It is worth mentioning that, typically, the term ZF
implies a definite number of amino-acid residues within the
protein, usually 30 to 40, with suitable metal-binding sites
composed of cysteines (Cys; monodentate or bridging) and
histidines (His). A key component of this system is the zinc ion
(Zn2+), which binds to the residues in a tetrahedral-based envi-
ronment providing essential elements of the structure. Release or
substitution of the central zinc ion, as well as mutation of
coordinating residues can result in a loss or impairment of the
biological function. For their essential multiple biological roles
ZF damage by oxidizing agents or redox-active metals has been
regarded as a novel mechanism of carcinogenesis.128 Interest-
ingly, the zinc-finger coordination environments are susceptible
to displacement of Zn2+ by other inorganic and transition metal
ions, which therefore are able to alter the zinc-finger domain
biological function.129
Within this frame, anticancer metal complexes have been
reported to efficiently interact with zinc-finger proteins and
enzymes, and, therefore, can be considered as possible medicinal
targets for this class of drugs. As an example, one of us recently
described the poly(adenosine diphosphate (ADP)-ribose) poly-
merase 1 (PARP-1) inhibition properties of different metal
compounds including cisplatin.130 PARPs are essential proteins
involved in cancer resistance to chemotherapies. PARPsplay a key
role in DNA repair by detecting DNA strand breaks and cata-
lysing poly(ADP-ribosylation),131 and consequently, PARPs have
been referred to as ‘‘the guardian angels’’ of DNA.132 Notably,
PARP-1, the most studied member of the PARP family, is char-
acterized by the presence of two long zinc fingers (ZF-PARPs, also
termed as nick-sensors), that are positioned upstream of the
catalytic domain,133 and mediate specific nicked DNA recogni-
tion.134 PARP has also been shown to bind to platinum-modified
DNA,135,136 and a systematic in vitro study was recently conducted
in which the effect of PARP inhibition on the ability of nuclear
proteins to bind platinum-modifiedDNAwas evaluatedby photo-
cross-linking experiments.137According to these results the activity
of PARP, following exposure to platinated DNA, resulted in the
dissociation ofDNA-boundproteins.Moreover, PARP inhibitors
were able to sensitize some, but not all, of the cell lines towards
cisplatin. Other studies describe the binding of PARP-1 to plat-
inum 1,2-d(GpG) and 1,3-d(GpTpG) intrastrand cross-links on
duplex DNA137,138 and a very recent report139 demonstrated that
PARP-1 differentiates between normal and platinum-damaged
DNA, having higher binding affinity for the cisplatin 1,2-d(GpG)
cross-links than for the unplatinated DNA or other types of
cisplatin–DNAcross-links.139 In this latter study it was also shown
that PARP-1 may shield theDNA lesion from repair and trigger a
cytotoxic response. Overall, despite these numerous studies, the
activity of PARP upon cisplatin treatment remains controversial
and not fully understood.
As mentioned above, transcription factors are another
important class of zinc-finger proteins. In this regard, it has beenThis journal is ª The Royal Society of Chemistry 2012shown that human DNA polymerase-a is inhibited by cisplatin
via coordination with the cysteine residues on the protein’s
C4-ZF motif.140 Ralph et al. have also shown by an ESI-MS
approach that platinum compounds can interfere with binding of
the transcription factor PU.1-DBD to a dsDNA molecule con-
taining its consensus-binding site.141 Moreover, cisplatin has also
been recently reported to affect the conformation of the apo-
form of the breast cancer susceptibility protein 1 (BRCA1)
RING finger domain forming intra- and intermolecular Pt-
BRCA1 adducts, where a preferential platinum-binding site was
found at His117.142 The same authors investigated the functional
consequences of the in vitro platination of the BRCA1 RING
domain by cisplatin and analogues, which resulted in the inhi-
bition of the ubiquitin ligase activity of BRCA1.143
Of note, platinum(II) complexes have been reported to interact
with the C-terminal finger of the HIV nucleocapsid NCp7 zinc
finger leading to zinc ejection.144 These latter studies show the
opportunity of exploiting metal-based drugs as new classes of
anti-HIV agents based on inhibition of HIV NCp7 function.
Recently, the same authors showed that a platinated single-
stranded oligonucleotide can alter the structure of a model ZF
peptide and characterized this interaction at a molecular level by
NMR spectroscopy.145 Most importantly, these results have
shown that the extent and rate of zinc displacement by inorganic
compounds can be modulated by the nature (metal, ligands) of
the reacting compound, and that DNA-tethered coordination
complexes may be designed to target specific ZF motifs.
5. Perspectives for new drug design and targeted
therapies
The knowledge of the possible reactivity of platinum complexes
with peptides and proteins is essential also for the development of
new targeted therapies for anticancer metallodrugs. From recent
years, among the most representative examples, we could list
Pt–HSA conjugates146 that exploit endogenous albumin as drug
carrier, since albumin is known to accumulate in solid tumours
via the enhanced permeability and retention (EPR) effect; the
latter being due to the pathophysiology of tumour tissues,
characterized by angiogenesis, hypervasculature, a defective
vascular architecture, and an impaired lymphatic drainage.
Modifications of the platinum carrier ligands and, to a lesser
extent, of the leaving groups have also been widely exploited for
achieving tumour tissue specificity. Among the possible ligands
several examples include the use of peptidic moieties to facilitate
platinum(II) uptake by peptide receptors.147–150 Several Pt(IV)-
peptide conjugates were also designed and synthesized for the
purpose of targeted drug delivery to tumour endothelial cells and
tumour cells expressing avb3/avb5 integrins.
151 The tri- and
pentapeptides, containing an RGD (Arg–Gly–Asp) motif,
attached by an amide linkage to the platinum(IV) center through
a succinato group (Fig. 4), served in this case as tumour-targeting
units. Similarly, a Pt(IV) complex conjugated to the cancer-tar-
geting peptide chlorotoxin (CTX) was synthesized in order to
deliver the compound selectively to cancer cells.152 Like most
Pt(IV) derivatives, the cytotoxicity of the conjugate was lower in
cell culture than that of cisplatin, but greater than those of its
Pt(IV) precursor and CTX in several cancer cell lines. Within this
frame, application of carbohydrate–Pt complexes is anotherChem. Sci., 2012, 3, 3135–3144 | 3141












































View Article Onlineexample of a targeted approach exploiting the biochemical and
metabolic functions of diverse sugars in living organisms for
transport and accumulation.153
In other cases, Pt complexes with ligands acting in synergy
with the metal centre to inhibit specific enzymes have been
developed (Fig. 4).154 Thus, diethyl[(methylsulfinyl)methyl]
phosphonate (SMP) ligands have been proposed to achieve bone
tissue specificity, and Pt–SMP compounds were designed in such
a way that the DNA-damaging property is associated with a non-
competitive inhibitory effect toward matrix metalloproteinase
(MMP) enzymes.155 Ethacraplatin (EA-CPT), a trans-Pt(IV)
carboxylate complex containing ethacrynate ligands (see Fig. 4),
was designed as a platinum anticancer metallodrug that could
also target cytosolic glutathione S-transferase (GST P1-1)
enzymes.156 Cytosolic GST enzymes constitute the main cellular
defence against xenobiotics, and they are known to catalyze the
conjugation of glutathione (GS-H) with cisplatin in vitro,157 the
first step in the mercapturic acid pathway that leads to elimina-
tion of toxic compounds. The same authors reported that EA-
CPT was an excellent inhibitor of GST activity in mammalian
cells compared to either cisplatin or ethacrynic acid.158 Following
this trend, Marmion et al. developed bifunctional platinum(II)
compounds with dual DNA binding and histone deacetylase
(HDAC) inhibitory activity of the type reported in Fig. 4 (the
Pt(II)-malSAHA compound).159,160 Finally, terpyridine–Pt(II)
complexes have been shown to be effective inhibitors of
mammalian topoisomerase enzymes,161 as well as of the seleno-
enzyme human thioredoxin reductase 1 (hTrxR1);162 both targets
offering possible novel strategies for future generations of che-
motherapic agents. Overall, in designing new Pt anticancer
drugs, it is now clear that considering only DNA-binding prop-
erties are not sufficient.6. Concluding remarks/summary and outlook
Platinum-based anti-cancer drugs are effective pharmaceuticals
and are still the most used agents against malignancies. In
parallel to the preparation and screening of platinum complexes3142 | Chem. Sci., 2012, 3, 3135–3144as potential anticancer agents, extensive efforts must be directed
at elucidating the mechanism of action of platinum-based drugs.
Numerous experimental evidences demonstrate that reactions
with proteins are fundamental in determining the overall phar-
macological and toxicological profile of platinum drugs.
Certainly, it is impossible to predict the reactivity of metal-
lodrugs with proteins or peptides in vivo only on the basis of
classical coordination experiments in aqueous solution. Only an
understanding of the cellular events that take place as a result of
exposure of cells/tissues to platinum drugs might lead to new
strategies for the preparation of novel platinum compounds with
improved therapeutic profiles.
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